

10/537301

JC17 Rec'd PCT/PTO 02 JUN 2005

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A pharmaceutical composition comprising a non-viable cell lysate and at least one antiflocculant and/or antisedimentation agent(s), wherein the antiflocculant and/or antisedimentation agent is xanthan gum.

2. (Original) The pharmaceutical composition of claim 1, wherein the antiflocculant and /or antisedimentation agent is a combination of xanthan gum and maltodextrin.

3. (Original) The pharmaceutical composition of claim 1 or 2 further comprising a buffering agent.

4. (Currently Amended) The pharmaceutical composition of ~~claims 1 to 3~~claim 1 in a dried form.

5. (Currently Amended) The pharmaceutical composition of ~~claims 1 to 3~~claim 1 in a freeze-dried form.

6. (Currently Amended) The pharmaceutical composition of ~~claims 1 to 5~~claim 1, wherein the cell lysate is a keratinocyte cell lysate.

7. (Currently Amended) The pharmaceutical composition of claim 1~~claims 1 to 6~~, wherein said composition further comprises at least one of a pharmaceutically acceptable carrier, excipient and vehicle~~carrier/excipient/vehicle~~.

8. (Currently Amended) A method~~The pharmaceutical composition of claims 1 to 7 for the purpose of promoting wound healing~~ comprising applying the composition of

claim 1 to an area skin in need of said promoting, wherein said composition comprises a non-viable cell lysate and a pharmaceutically acceptable vehicle.

9. (Currently Amended) The pharmaceutical composition of claim 7~~claims 7 or 8~~, wherein said pharmaceutically acceptable vehicle is a dry powder, a suspension or a solution.

10. (Currently Amended) The pharmaceutical composition of claim 7~~claims 7 or 8~~, wherein said pharmaceutically acceptable vehicle is a gel, cream, ointment or a biocompatible matrix.

11. (Original) A process for the production of a homogenized pharmaceutical composition comprising the steps of growing, lysing and drying the cells, which process is characterized in that, immediately after lysing, antiflocculant and/or antisedimentation agents are added to stabilize the cell lysate mixture, wherein the antiflocculant/antisedimentation agent is xanthan gum.

12. (Original) A process of claim 11 wherein drying the cells is by freeze-drying.

13. (Currently Amended) A process of claims~~claim~~ 11 or 12, wherein cell the lysate is a keratinocyte cell lysate.

14. (Currently Amended) A process of claims~~claim~~ 11 to 13 wherein the antiflocculant and/or antisendimentation agent is a combination of xanthan gum and maltodextrin.

15. (Currently Amended) The method of claim 8 wherein said wound is at least one of a Use of the composition of claim 1 to 10 for the treatment of burn wounds or skin ulcers~~wound and a skin ulcer.~~

VERVAET et al.
U.S. National Phase of PCT/EP2003/050891

16. (new) The method of claim 8 wherein said composition is in the form of a dry powder, a suspension or a solution.

17. (new) The method of claim pharmaceutical composition of claim 8 wherein said composition is in the form of a gel, a cream, an ointment or a biocompatible matrix.